Aktiesnakken — Oktober 2010
-
iøvrigt colombuss, har jeg også investeret i glaxo og det går ret godt....
-
og masser af udbytte. Johnsen skulle måske også have sig et nyt eventyr udi det medicinske
-
jeg tror gsk har lavet den rigtige strategi.
-
nye markeder og så dem der løser patent cliff bedst
-
måske kan exiqon godt være positioneret for et eller andet.....hvis de ikke må rejse penge. Synes lundbecks udmelding om målrettet medicin
-
godt kan være en invitation
-
godmorgen karbold
-
ja det har jeg bemærket
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind